ANA Seroconversion Psoriasis Biologics Supplementary Data
Description
Supplementary material for a systematic review submitted to JAAD Reviews. Contains: (1) Supplementary Methods detailing search strategy, eligibility criteria, and quality assessment procedures; (2) Supplementary Discussion with extended mechanistic interpretation of ANA seroconversion across biologic classes; (3) Supplementary Table S1 with characteristics of three included prospective cohort studies (280 patients); (4) Supplementary Figure S1 (PRISMA 2020 flow diagram); and (5) Supplementary References S6-S26.
Files
Steps to reproduce
Systematic literature search of PubMed/MEDLINE, Scopus, and Web of Science from inception through November 2025. Study selection, data extraction, and quality assessment (Newcastle-Ottawa Scale, GRADE) performed by two independent reviewers. Full search strategy and eligibility criteria detailed in the supplementary methods file. Protocol registered in PROSPERO (CRD420251238193).
Institutions
- National Taiwan University HospitalTaiwan, Taipei